Combining testosterone therapy with regular exercise, structured sleep, and mindfulness interventions can greatly enhance emotional equilibrium. In contrast, testosterone undecanoate, with its long half-life, provides a steadier emotional baseline. For such patients, urologists often recommend dividing the dose into smaller, more frequent injections for instance, every seven days instead of every fourteen to achieve a smoother hormonal curve. The term "trough level" refers to the lowest point in serum testosterone concentration before the next scheduled injection. Unlike most medications with straightforward dosing, testosterone therapy requires careful titration – not only to normalize laboratory numbers but to stabilize symptoms. Once a urologist selects the appropriate testosterone ester, the next challenge lies in maintaining the right serum concentration over time.
By contrast, testosterone undecanoate is a long-acting ester, with a half-life of approximately 10–12 weeks. Meanwhile, long-acting injectables, specifically testosterone undecanoate, require decreased frequency of administration, with some manufacturers recommending dosing only at weeks 0 and 4 and then every 10 weeks thereafter16. The purpose of TT is to restore and maintain hormone levels at the physiologic serum concentration in order to alleviate symptoms of testosterone deficiency without causing significant side effects or safety concerns7.
It appears that in women, rather than testosterone, estradiol may be the most important hormone involved in sexual desire, although data on the clinical use of estradiol to increase sexual desire in women is limited. The reasons cited were limited efficacy (about one additional sexually satisfying event per month), concerns about safety and potential adverse effects with long-term therapy, and concerns about inappropriate off-label use. In 2003, the FDA rejected Intrinsa, a 300 μg/day testosterone patch for the treatment of sexual dysfunction in postmenopausal women. The high doses of testosterone required to increase sexual desire in women may have a significant risk of masculinization with long-term therapy. In contrast to these high doses, there is little support for the notion that testosterone is a critical hormone for sexual desire and function in women under normal physiological circumstances. These included decreased levels of total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol, and increased levels of low-density lipoprotein (LDL) cholesterol. They recommend yearly evaluation regarding possible improvement and, if none, to discontinue testosterone; physicians should consider intramuscular treatments, rather than transdermal treatments, due to costs and since the effectiveness and harm of either method is similar.
Data suggest that, in general, medications that require long-term administration have compliance rates between 40% and 50% (54). The most frequent events were erythrocytosis (21 men; 7 discontinued), hypertension (19 men; 1 discontinued), and increase in serum prostate-specific antigen of 1.4 ng/mL or greater from baseline (18 men; 13 discontinued) (27). The majority of these events were mild to moderate, although 5 patients experienced severe events. Four participants reported small, painless nodules that resolved within 2 days, while 2 participants developed urticaria at the injection site within a few hours that persisted for up to 3 days. In addition, there is no risk of sciatic injury, administration can be accomplished using smaller needles, and the pain evoked during SC administration is usually lower. The formulation contains 250 mg/mL of the ester dissolved in castor oil and is supplied in 3-mL vials in the United States, and 4-mL vials in other parts of the world.
While both short-acting and long-acting T have been shown to restore normal T levels, there are significant differences between the two modalities. Additionally, these societies suggest that free testosterone can be used if there is a low-normal total T measurement and/or sex hormone binding globulin (SHBG) levels are abnormal13. However, coinciding with an FDA communication about potential cardiovascular events following testosterone therapy, there was a decrease of 3.2% use of testosterone in men in 2013 to 1.67% in 2016, with new users decreasing from 1.26% to 0.48%5. In the latter case, the supraphysiologic dosing of testosterone exploits the androgenic effects on muscle, bone, and other tissues in men, especially in eugonadal patients1. Short-acting pharmacology mimics normal physiology more closely than long-acting TT but requires multiple doses per day, while long-acting TT has a higher rate of patient adherence but is more likely to create supraphysiologic serum testosterone and pathologic sequelae. Prescriptions for testosterone therapy (TT) to treat testosterone deficiency have increased in recent years. In a controlled study, Testavan provided higher bioavailable testosterone and delivering more testosterone in a smaller amount of gel when compared to Androgel.
Androgel expanded its line to include a 1.62% testosterone gel strength in April of 2013. Approximately 9-14% of the testosterone in the gel is available and active. Androgel 1% is a colorless gel that contains 25 or 50mg of testosterone dissolved in 2.5 or 5g of gel. In 2000 Androgel ™ 1% became the first testosterone gel approved for use in the United States by the FDA. Jatenzo is a combination of a testosterone molecule attached to a fatty acid.